LIVN · Analysis updated Nov 4, 2026, 4:12 PM ET

Why is LivaNova PLC (LIVN) stock moving?

LivaNova's third-quarter revenue rose 9.9% to $393.1 million (10.0% in constant currency), with heart-surgery equipment up 10.9% and epilepsy devices up 11.1%. Adjusted earnings of $1.23 a share beat the roughly $1.08 expected by about 14%, though reported (GAAP) earnings fell to $0.11 from $0.49 on higher legal and other charges. The company raised its 2026 constant-currency revenue growth outlook to 9-10% (from 8-9%) and adjusted earnings to $4.40-4.50 a share (from $4.30-4.40), its third raise this year after starting at 6-7% growth. The stock closed up about 18% at $94.19 after hitting $99.38, a 52-week high.

News behind the analysis

LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
Business Wire · Nov 3, 2026
Revenue $393.1M (+9.9%); adjusted EPS $1.23; 2026 growth outlook raised to 9-10%.
LivaNova Stock Jumps as Double-Digit Growth and Third Straight Guidance Raise Fuel Medical Device Maker Rally
IBTimes Australia · Nov 3, 2026
Third straight guidance raise; both segments grew double digits.
LivaNova (NASDAQ:LIVN) Q3 2026: Adjusted EPS Beat, Revenue Inline, Guidance Raised
ChartMill · Nov 3, 2026
Adjusted EPS beat; early dip on lower GAAP profit.
Policy relief sparks surge in health insurance and hospital stocks
Investing.com · Nov 3, 2026
Healthcare stocks rallied after the midterm results; medical-device makers rose about 7%.

In the Daily Standout

November 4, 2026: on the shortlist +17.88%

For informational and educational purposes only. Not investment advice. Prices are a snapshot at the close and move quickly; sentiment and confidence scores are model opinions, not guarantees. Do your own research.